Who was studied?
Planned enrollment: 30 patients with recurrent or metastatic refractory NSCLC.
What does the publication report?
A single-center, single-arm phase II study is planned with ORR as its primary endpoint.
Safety findings
Adverse events will be assessed prospectively; observed safety results are not reported.
How should we interpret it?
This is a study protocol, not a report of treatment results. Planned enrollment and endpoints are not observed outcomes.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Endostar combined with PD-1 blockade, radiotherapy, GM-CSF, and IL-2 (PRaG 2.0E) for refractory non-small cell lung cancer: a single-arm, phase II clinical trial (PRaG2.0E Study Protocol) · DOI: 10.21037/tlcr-2026-1-0203 · PMID: 42291342
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.